Effect of prolyl hydroxylase domain-2 haplodeficiency on the hepatocarcinogenesis in mice

Journal of Hepatology

Volumn 57, Issue 1, 2012, Pages 61-68

  Heindryckx, Femke ^a   Kuchnio, Anna ^b,c   Casteleyn, Christophe ^d   Coulon, Stephanie ^a   Olievier, Kim ^a   Colle, Isabelle ^a   Geerts, Anja ^a   Libbrecht, Louis ^a   Carmeliet, Peter ^b,c   Van Vlierberghe, Hans ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Angiogenesis; Cholangiocarcinoma; Hepatic progenitor cells; Hepatocellular carcinoma; Hypoxia; Notch signaling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERCELLULAR ADHESION MOLECULE 1; JAGGED1; NOTCH1 RECEPTOR; OCTAMER TRANSCRIPTION FACTOR 4; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; CELL ACTIVATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HAPLOINSUFFICIENCY; LIVER CARCINOGENESIS; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; WILD TYPE;

ALKYLATING AGENTS; ANIMALS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HEPATITIS; HUMANS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; PHENOTYPE; PRECANCEROUS CONDITIONS; PROCOLLAGEN-PROLINE DIOXYGENASE; SIGNAL TRANSDUCTION; STEM CELLS;

EID: 84862665190     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2012.02.021     Document Type: Article

References (33)

1. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int 2011;31:146-162.
2. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation 2007;116:774-781.
3. Chan DA, Kawahara TLA, Sutphin PD, Chang HY, Chi J-T, Giaccia AJ. Tumor vasculature is regulated by PHD2-mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 2009;15:527-538.
4. Henze AT, Riedel J, Diem T, Wenner J, Flamme I, Pouyseggur J, et al. Prolyl hydroxylases 2 and 3 act in gliomas as protective negative feedback regulators of hypoxia-inducible factors. Cancer Res 2010;70:357-366.
5. Mazzone M, Dettori D, Dettori D, Leite de Oliveira R, Loges S, Schmidt T, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009;136:839-851.
6. Su Y, Loos M, Giese N, Metzen E, Buchler MW, Friess H, et al. Prolyl hydroxylase-2 (PHD2) exerts tumor-suppressive activity in pancreatic cancer. Cancer 2011 (ePub).
7. Chan DA, Giaccia AJ. PHD2 in tumor angiogenesis. Br J Cancer 2010;103:1-5.
8. Heindryckx F, Mertens K, Charette N, Vandeghinste B, Casteleyn C, Van Steenkiste C, et al. Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma. Mol Cancer 2010;9:219.
9. Van de Veire S, Stalmans I, Heindryckx F, Oura H, Tijeras-Raballand A, Schmidt T, et al. Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. Cell 2010;141:178-190.
10. Yang H, Li TW, Peng J, Tang X, Ko KS, Xia M, et al. A mouse model of cholestasis-associated cholangiocarcinoma and transcription factors involved in progression. Gastroenterology 2011;141:378-388, 388e1-4.
11. Rogers AB, Theve EJ, Feng Y, Fry RC, Taghizadeh K, Clapp KM, et al. Hepatocellular carcinoma associated with liver-gender disruption in male mice. Cancer Res 2007;67:11536-11546.
12. Pilette C, Rousselet MC, Bedossa P, Chappard D, Oberti F, Rifflet H, et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol 1998;28:439-446.
13. Van Steenkiste C, Ribera J, Geerts A, Pauta M, Tugues S, Casteleyn C, et al. Inhibition of placental growth factor activity reduces the severity of fibrosis, inflammation, and portal hypertension in cirrhotic mice. Hepatology 2011;53:1629-1640.
14. Spee B, Carpino G, Schotanus BA, Katoonizadeh A, Vander Borght S, Gaudio E, et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010;59:247-257.
15. Woo HG, Lee JH, Yoon JH, Kim CY, Lee HS, Jang JJ, et al. Identification of a cholangiocarcinoma-like gene expression trait in hepatocellular carcinoma. Cancer Res 2010;70:3034-3041.
16. El-Khoueiry AB, Rankin CJ, Ben-Josef E, Lenz H-J, Gold PJ, Hamilton RD, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs 2011. http://dx.doi.org/10.1007/s10637-011-9719-0, [Epub ahead of print].
17. Lee KA, Lynd JD, O'Reilly S, Kiupel M, McCormick JJ, LaPres JJ. The biphasic role of the hypoxia-inducible factor prolyl-4-hydroxylase, PHD2, in modulating tumor-forming potential. Mol Cancer Res 2008;6:829-842.
18. Elser JJ, Nagy JD, Kuang Y. Biological stoichiometry: an ecological perspective on tumor dynamics. Bioscience 2003;53:1112-1120.
19. Kawahara N, Ono M, Taguchi K, Okamoto M, Shimada M, Takenaka K, et al. Enhanced expression of thrombospondin-1 and hypovascularity in human cholangiocarcinoma. Hepatology 1998;28:1512-1517.
20. Schmidt T, Kharabi Masouleh B, Loges S, Cauwenberghs S, Fraisl P, Maes C, Schmidt T, et al. Loss or inhibition of stromal-derived PlGF prolongs survival of mice with imatinib-resistant Bcr-Abl1(+) leukemia. Cancer Cell 2011;19:740-753.
21. Ameln AK, Muschter A, Mamlouk S, Kalucka J, Prade I, Franke K, et al. Inhibition of HIF prolyl hydroxylase-2 blocks tumor growth in mice through the antiproliferative activity of TGFbeta. Cancer Res 2011;71: 3306-3316.
22. Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res 2010;16:5928-5935.
23. Roncalli M, Park YN, Di Tommaso L. Histopathological classification of hepatocellular carcinoma. Digest Liver Dis 2010;42:S228-S234.
24. Roskams T. Liver stem cells and their implication in hepatocellular and cholangiocarcinoma. Oncogene 2006;25:3818-3822.
25. Anilkumar TV, Golding M, Edwards RJ, Lalani EN, Sarraf CE, Alison MR. The resistant hepatocyte model of carcinogenesis in the rat: the apparent independent development of oval cell proliferation and early nodules. Carcinogenesis 1995;16:845-853.
26. Bralet M-P, Pichard V, Ferry N. Demonstration of direct lineage between hepatocytes and hepatocellular carcinoma in diethylnitrosamine-treated rats. Hepatology 2002;36:623-630.
27. Jin LF, Ji SH, Yang JF, Ji WZ. Notch signaling dependent differentiation of cholangiocyte-like cells from rhesus monkey embryonic stem cells. Zoo Res 2011;32:391-395.
28. Beaussier M, Wendum D, Fouassier L, Rey C, Barbu V, Lasnier E, et al. Adaptative bile duct proliferative response in experimental bile duct ischemia. J Hepatol 2005;42:257-265.
29. Fouassier L, Beaussier M, Schiffer E, Rey C, Barbu V, Mergey M, et al. Hypoxia-induced changes in the expression of rat hepatobiliary transporter genes. AMJ Phys 2007;293:G25-G35.
30. Sapisochin G, Fidelman N, Roberts JP, Yao FY. Mixed hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma in patients undergoing transplantation for hepatocellular carcinoma. Liver Transplant 2011;17:934-942.
31. Zen C, Zen Y, Mitry RR, Corbeil D, Karbanova J, O'Grady J, et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation. Liver Transplant 2011;17:943-954.
32. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-231.
33. Yoneda N, Sato Y, Kitao A, Ikeda H, Sawada-Kitamura S, Miyakoshi M, et al. Epidermal growth factor induces cytokeratin 19 expression accompanied by increased growth abilities in human hepatocellular carcinoma. Lab Invest 2011;91:262-272.